Amgen Vectibix Cap Cuts Patient Cost, But Will Payers Balk At High Price?

Amgen announced a program to limit patients' out-of-pocket cost for Vectibix, following FDA approval of panitumumab Sept. 27.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet